Christopher L Bowlus MD

Clinical Trials

• Initial Study of Rituximab to Treat Primary Biliary Cirrhosis Start of enrollment: 2007 Jan 01

  Completed

  Phase 1, Phase 2

• Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease Start of enrollment: 2007 Oct 01

  Terminated

  Phase 2

• Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2012 Jan 01

  Completed

  Phase 3

• Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) Start of enrollment: 2013 Mar 04

  Completed

  Phase 2

• Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis Start of enrollment: 2013 Dec 03

  Completed

  Phase 2

• Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2013 Aug 01

  Completed

  Phase 2

• Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Start of enrollment: 2014 Mar 01

  Completed

  Phase 2

• Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Start of enrollment: 2014 Sep 01

  Completed

  Phase 4

• Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Start of enrollment: 2015 Feb 09

  Completed

  Phase 2

• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Start of enrollment: 2014 Dec 26

  Terminated

  Phase 4

• An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis Start of enrollment: 2015 May 01

  Withdrawn

  Phase 2

• Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients Start of enrollment: 2015 May 01

  Completed

• Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies Start of enrollment: 2016 Apr 30

  Completed

  Phase 2

• Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) Start of enrollment: 2015 Nov 04

  TERMINATED

  PHASE2

• PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis Start of enrollment: 2016 Mar 14

  Completed

  Phase 2

• A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

  COMPLETED

• Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis Start of enrollment: 2016 Dec 01

  Terminated

  Phase 2

• Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Start of enrollment: 2016 Nov 29

  Completed

  Phase 2

• Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) Start of enrollment: 2016 Nov 28

  Completed

  Phase 2

• Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. Start of enrollment: 2017 Jun 26

  Completed

  Phase 2

• Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Start of enrollment: 2017 Dec 12

  ACTIVE_NOT_RECRUITING

  PHASE3

• Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis Start of enrollment: 2018 Jul 01

  Recruiting

  Phase 2

• CM-101 in PSC Patients -The SPRING Study Start of enrollment: 2020 Oct 01

  Active, not recruiting

  Phase 2

  Roles: Contact

• Join now to see all